Repeats from Monday with no changes
** Shares of Johnson & Johnson JNJ.N rise 1% to $153.42 on Mon ahead of its first quarter results due before the market open on Tues with investors focused on how the pharmaceutical giant is dealing with tariffs imposed by President Donald Trump
** Trump announced a 90-day freeze on some of his new tariffs but left in place 10% tariffs on most U.S. imports
** Analysts expect JNJ to report rev of ~$21.57 bln, flat from a year ago, and EPS of $2.59, down ~4.5% from a year ago
** Among 26 analysts that cover JNJ, avg rating is "BUY" and median PT is $169.50, per LSEG data
** JNJ's rev has exceeded expectations 7 times over the last 8 quarters, while EPS has met estimates every time
** JNJ is up 6.4% YTD compared with the S&P 500 health index .SPXHC, which is up just ~6%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。